https://www.selleckchem.com/pr....oducts/pqr309-bimira
Out of 641 patients, 106 patients (17%) experienced grade ≥3 irAEs. None of the analysed factors were associated with grade ≥3 irAE occurrence in the monotherapy (n=55 or the combination therapy (n=91) groups, nor in the subgroup analyses. Of interest, none of the patients with NSCLC with a WHO performance status of 0 (n=34) experienced grade ≥3 irAEs. Most common NSCLC histology types were adenocarcinoma (n=99/55%) and squamous cell carcinoma (n=39/22%). This study shows that patient and disease characteristics are not abl
Like
Comment
Share
